Anyone else have this?: There is a monoclonal protein present overlying transferrin in the beta region that measures between 0.8 and 1.3 g/dl with suppression of polyclonal immunoglobulins. Immunofixation electrophoresis is consistent with the previously identified IgA kappa monoclonal gammopathy. The monoclonal protein cannot be accurately measured with this methodology. IFE also shows a small free kappa monoclonal protein (monoclonal protein #2) in the alpha-2 region.
I ask my Dr and am just told the disease is "progressing"?? Since for 10 yrs I've watched the mspike, now not sure how well the meds are working since light chains are very high. Am on dara faspro and Pom this year and not seeing results but have to keep stopping the Pom due to low blood cells...Keep reading about other new meds like Ventaclave, etc?? My beta 2 is very high and i wonder what can bring that down? Thanks and happy holidays.

Your Feed
Filter by
See content from
Playlist: ASH 2023
Use of Biomarkers to Predict CAR-T Outcomes | Darren Pan, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Addressing Racial and Ethnic Disparities in AML Clinical Trials | Andrew Hantel, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Study on Minimizing Exclusion for AML Patients in Clinical Trials | Andrew Hantel, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Loncastuximab for High-Risk Relapsed/Refractory FL | Juan Pablo Alderuccio, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Costs & Financial Hardship Among BMT CTN 1102 Patients MDS | Christopher Su, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Trial of an Education Video for CAR T-cell Therapy Recipients
Video details & playlist
Playlist: ASH 2023
Costs of Venetoclax-Obinutuzumab vs. BTKi in CLL | Scott Huntington, MD, MPH, MSc | ASH 2023
Video details & playlist
Playlist: ASH 2023
Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Exploring Drug Options for MDS Patients with XPO1 Inhibitors | Justin Taylor, MD & Sana Chaudhry, BS | ASH 2023
Video details & playlist
Playlist: ASH 2023
Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Fighting DLBCL by Attacking the Microenviroment | Leandro Cerchietti, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Older Patients Experience Improved QOL with NHL Treatments
Video details & playlist
Playlist: ASH 2023
Effects of Stem Cell Infusion with BCMA CAR-T | Meera Mohan, MD | ASH 2023
Video details & playlist
Playlist: ASH 2023
Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023
Video details & playlist



